Abstract
Infusion of donor bone marrow (DBM)-derived cells continue to be tested in clinical protocols intended to induce specific immunologic tolerance. Central clonal deletion of donor-specific alloreactive cells associated with mixed chimerism reliably produced long-term graft tolerance. In this setting, depletion of recipient T cells by antilymphocyte antibodies and subsequent repopulation by donor hematopoietic cells after donor bone marrow infusion (DBMI) are prerequisites for tolerance induction. Major advances have been made in animal models and in pilot clinical trials and the key questions with the future perspectives are presented in this article.
| Original language | English |
|---|---|
| Pages (from-to) | 105-115 |
| Number of pages | 11 |
| Journal | Transplant Immunology |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| State | Published - Sep 1 2004 |
Fingerprint
Keywords
- Bone marrow transplant
- Chimerism
- Tolerance
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
- Transplantation
Cite this
Donor bone marrow transplantation : Chimerism and tolerance. / Delis, Spiros; Ciancio, Gaetano; Burke, George W; Garcia-Morales, Rolando; Miller, Joshua.
In: Transplant Immunology, Vol. 13, No. 2, 01.09.2004, p. 105-115.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Donor bone marrow transplantation
T2 - Chimerism and tolerance
AU - Delis, Spiros
AU - Ciancio, Gaetano
AU - Burke, George W
AU - Garcia-Morales, Rolando
AU - Miller, Joshua
PY - 2004/9/1
Y1 - 2004/9/1
N2 - Infusion of donor bone marrow (DBM)-derived cells continue to be tested in clinical protocols intended to induce specific immunologic tolerance. Central clonal deletion of donor-specific alloreactive cells associated with mixed chimerism reliably produced long-term graft tolerance. In this setting, depletion of recipient T cells by antilymphocyte antibodies and subsequent repopulation by donor hematopoietic cells after donor bone marrow infusion (DBMI) are prerequisites for tolerance induction. Major advances have been made in animal models and in pilot clinical trials and the key questions with the future perspectives are presented in this article.
AB - Infusion of donor bone marrow (DBM)-derived cells continue to be tested in clinical protocols intended to induce specific immunologic tolerance. Central clonal deletion of donor-specific alloreactive cells associated with mixed chimerism reliably produced long-term graft tolerance. In this setting, depletion of recipient T cells by antilymphocyte antibodies and subsequent repopulation by donor hematopoietic cells after donor bone marrow infusion (DBMI) are prerequisites for tolerance induction. Major advances have been made in animal models and in pilot clinical trials and the key questions with the future perspectives are presented in this article.
KW - Bone marrow transplant
KW - Chimerism
KW - Tolerance
UR - http://www.scopus.com/inward/record.url?scp=4544246588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4544246588&partnerID=8YFLogxK
U2 - 10.1016/j.trim.2004.05.006
DO - 10.1016/j.trim.2004.05.006
M3 - Article
C2 - 15380541
AN - SCOPUS:4544246588
VL - 13
SP - 105
EP - 115
JO - Transplant Immunology
JF - Transplant Immunology
SN - 0966-3274
IS - 2
ER -